<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106977</url>
  </required_header>
  <id_info>
    <org_study_id>050131</org_study_id>
    <secondary_id>05-HG-0131</secondary_id>
    <nct_id>NCT00106977</nct_id>
  </id_info>
  <brief_title>Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)</brief_title>
  <official_title>Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will explore the range and type of medical and developmental problems in patients
      with Muenke syndrome, a condition that results when one or more of the suture between the
      bones of the skull close before birth. Because of the premature closure, the skull is not
      able to grow in its natural shape; instead, it compensates with growth in areas of the skull
      where the sutures have not yet closed. This can result in an abnormally shaped head, wide-set
      eyes, and flattened cheekbones. Patients may also have an enlarged head, abnormalities of the
      hands or feet, and hearing loss.

      The fibroblast growth factor receptor 3 (FGFR3) gene, which is involved in the development
      and maintenance of bone tissue, plays a role in Muenke syndrome. In some cases, the FGFR3
      mutation is inherited from a parent with Muenke syndrome; in other cases, where there is no
      family history of the disorder, the mutation occurs anew. A better understanding of this gene
      may lead researchers to develop better treatments and genetic counseling for people affected
      by Muenke syndrome.

      Patients with Muenke syndrome and their blood relatives may be eligible for this study.
      Family members with confirmed Muenke syndrome will have genetic counseling, and patients
      undergo the following tests and procedures:

        -  Review of medical records and test results.

        -  Questionnaires about the patient's prenatal, birth, newborn, and past medical history;
           family history; growth and development; medications; and current therapies.

        -  Physical, neurological, ear, nose and throat, dental, and eye examinations.

        -  Neuropsychological testing to assess cognitive thinking abilities.

        -  Hearing evaluation. This includes an audiology test in which the patients listens to
           soft tones through earphones; a power reflectance test in which a chirping sound is
           heard through an earpiece placed at the entrance to the ear canal, and possibly an
           ABR/ASSR test, in which electrodes are attached to the forehead, earlobes, and behind
           the ears to measure brain waves in response to certain conditions.

        -  MRI scan of the brain. MRI uses a strong magnetic field and radio waves to produce
           detailed pictures of the brain. During the scan, the patient lies on a table in a narrow
           cylinder (the scanner), wearing ear plugs to muffle loud noises that occur with
           electrical switching of the magnetic fields.

        -  MRI scan of the middle and inner ear. This test is similar to the MRI, but uses a dye
           injected in a vein to enhance the images.

        -  CT scan of the skull. CT uses x-rays to produce 3-dimensional images of the part of the
           body studied.

        -  Dental evaluation with x-rays.

        -  Skeletal survey (x-rays of all bones of the body).

        -  Developmental assessment of IQ testing.

        -  Blood tests for research purposes. A cell line may be established for use in future
           research.

        -  Medical photographs to demonstrate clinical features, including side and front views of
           the face, head, and other parts of the body that may be involved in Muenke syndrome,
           like the hands and feet.

        -  Other consultations or tests as clinically indicated
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Craniosynostosis is a common craniofacial abnormality caused by premature fusion of one or
      several sutures of the skull. The prevalence of craniosynostosis is approximately 1 in 2,100
      to 3,000 births. Originally described by our group, Muenke syndrome (OMIM # 602849) is a
      specific form of craniosynostosis caused by a single nucleotide transversion in fibroblast
      growth factor receptor 3 (FGFR3), c.749C&gt;G, resulting in p.Pro250Arg. Individuals carrying
      the defining mutation variably manifest coronal suture craniosynostosis, developmental delay,
      deafness, and carpal and tarsal bone fusion. The purpose of the present study is to increase
      our understanding of the clinical manifestations of Muenke syndrome through detailed
      physical, developmental, neurologic, dental, ophthalmologic, otolaryngologic, audiologic,
      radiologic, and genetic/genomic studies. We also plan to examine the spectrum of clinical
      characteristics of Muenke syndrome to facilitate early diagnosis and clinical management,
      including genetic counseling. To accomplish this, we plan to enroll approximately 10-20
      probands, as well as their family members each year, with an enrollment ceiling of 200
      probands. Our study has three arms. The clinical arm is the major focus of our study.
      Patients and their families will be seen at the NIH Clinical Center and Children's National
      Medical Center. Individuals with Muenke syndrome who are unable or unwilling to come to the
      NIH, can submit their medical records, including a copy of the molecular testing, for review.
      The second arm is genetic/genomic studies with the goal of investigating modifying factors
      that relate to disease severity and expression. The third arm consists of a cognitive
      function, development and hearing questionnaire to be completed by patients online, via phone
      or mail.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 31, 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Craniosynostosis</condition>
  <condition>Muenke Syndrome</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Subjects who have had confirmation of a Pro250Arg mutation in FGFR3 by a CLIA-certified
        laboratory. Our research team must receive a photocopy of the positive test result in order
        to enroll a patient in the study. All races and genders are known to be at risk for Muenke
        syndrome. Nationality or place of origin is not a specific barrier to participation.

        Family members (typically parents or siblings) of probands with Muenke syndrome are also
        eligible to participate.

          -  Since the penetrance of Muenke syndrome is incomplete, any at risk individual will be
             given the option of enrolling in the research study for FGFR3 testing. Those
             individuals who are found to carry the p.Pro250Arg mutation may benefit from
             interventions like hearing screening or speech evaluations that would alter their
             medical management. Variable expressivity is another characteristic of Muenke syndrome
             and carrier status and adequate genetic counseling are important. Individuals with the
             mutation will be invited to participate in the clinical and/or medical record review
             arms of the study

          -  Unaffected family members of a proband enrolled in the clinical protocol may choose to
             provide a blood sample and/or participate in the behavioral arm of the study. These
             information will be used only for purposes of further research on Muenke syndrome.

        Patient of interest cases. Geneticists and genetic counselors may refer individuals who are
        suspected to have Muenke syndrome, but who have not yet been tested for the FGFR3 Pro250Arg
        mutation. The purpose of enrolling these subjects is to evaluate a wider spectrum of
        patients for the mutation causing Muenke syndrome. Testing for the Pro250Arg mutation maybe
        performed at the discretion of our research group. Those individuals who are found to carry
        the Pro250 Arg mutation may be invited to participate in the clinical study arm and/or
        medical record review arm of the study. While we do not incomplete penetrance, children who
        are not eligible for enrollment due to lack of physical findings consistent with Muenke
        Syndrome will be referred for hearing testing, and further testing if indicated.

        EXCLUSION CRITERIA:

          -  Anyone unwilling to provide informed consent (for themselves as adults, or on behalf
             of their children as minors) or assent.

          -  We reserve the right to exclude individuals for whom the medical risks of travel and
             evaluation at NIH appear to outweigh the benefits of study participation.

        Description and justification of inclusion/exclusion of participants. (age, gender,
        ethnicity, prisoners, pregnant women, fetuses, decisionally-impaired, healthy volunteers,
        lab personnel)

        It is our intention to remove as many economic, cultural, geographic, racial, and gender
        barriers as we reasonably can to promote participation of individuals with Muenke syndrome
        and their families for research purposes. The study will include pediatric and
        decisionally-impaired individuals, because these characteristics are possible with Muenke
        syndrome. Pregnant or nursing women may be limited in their participation in some aspects
        of the study (e.g. ionizing radiation exposure).

        As described above, Muenke syndrome has been demonstrated to occur in persons of different
        ethnic backgrounds. We would make every reasonable effort to encourage the enrollment and
        participation of a wide spectrum of individuals.

        -Pregnant women will not be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maximilian Muenke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Human Genome Research Institute (NHGRI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul S Kruszka, M.D.</last_name>
    <phone>(301) 402-9654</phone>
    <email>kruszkaps@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maximilian Muenke, M.D.</last_name>
    <phone>(301) 402-8167</phone>
    <email>mamuenke@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2005-HG-0131.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Bellus GA, Gaudenz K, Zackai EH, Clarke LA, Szabo J, Francomano CA, Muenke M. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet. 1996 Oct;14(2):174-6.</citation>
    <PMID>8841188</PMID>
  </reference>
  <reference>
    <citation>Muenke M, Gripp KW, McDonald-McGinn DM, Gaudenz K, Whitaker LA, Bartlett SP, Markowitz RI, Robin NH, Nwokoro N, Mulvihill JJ, Losken HW, Mulliken JB, Guttmacher AE, Wilroy RS, Clarke LA, Hollway G, Ad√®s LC, Haan EA, Mulley JC, Cohen MM Jr, Bellus GA, Francomano CA, Moloney DM, Wall SA, Wilkie AO, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet. 1997 Mar;60(3):555-64.</citation>
    <PMID>9042914</PMID>
  </reference>
  <reference>
    <citation>Moloney DM, Wall SA, Ashworth GJ, Oldridge M, Glass IA, Francomano CA, Muenke M, Wilkie AO. Prevalence of Pro250Arg mutation of fibroblast growth factor receptor 3 in coronal craniosynostosis. Lancet. 1997 Apr 12;349(9058):1059-62.</citation>
    <PMID>9107244</PMID>
  </reference>
  <verification_date>May 7, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2005</study_first_submitted>
  <study_first_submitted_qc>April 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2005</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Craniosynostosis</keyword>
  <keyword>Hearing Loss</keyword>
  <keyword>Genectic Disorders</keyword>
  <keyword>Muenke Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Craniosynostoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

